A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias.

Trial Profile

A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Leukaemia; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top